Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$14.1 million.

  • Phathom Pharmaceuticals' Free Cash Flow rose 7777.01% to -$14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$225.4 million, marking a year-over-year increase of 901.8%. This contributed to the annual value of -$266.9 million for FY2024, which is 9172.28% down from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Free Cash Flow of -$14.1 million as of Q3 2025, which was up 7777.01% from -$62.8 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Free Cash Flow registered a high of -$14.1 million during Q3 2025, and its lowest value of -$85.0 million during Q1 2025.
  • For the 4-year period, Phathom Pharmaceuticals' Free Cash Flow averaged around -$47.7 million, with its median value being -$44.3 million (2023).
  • Per our database at Business Quant, Phathom Pharmaceuticals' Free Cash Flow crashed by 21868.41% in 2024 and then surged by 7777.01% in 2025.
  • Phathom Pharmaceuticals' Free Cash Flow (Quarter) stood at -$41.5 million in 2022, then fell by 6.8% to -$44.3 million in 2023, then plummeted by 43.34% to -$63.5 million in 2024, then surged by 77.72% to -$14.1 million in 2025.
  • Its Free Cash Flow stands at -$14.1 million for Q3 2025, versus -$62.8 million for Q2 2025 and -$85.0 million for Q1 2025.